bivalirudin (Angiomax)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Angiomax.

Indications

Contraindications

Pharmacokinetics

Adverse effects

Overdose

Mechanism of action

Clinical trials

More general terms

References

  1. Prescriber's Letter 8(2):11 2001
  2. Jump up to: 2.0 2.1 Stone GW et al, for the ACUITY Investigators Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17124018
    Bittl JA Accounting for Acuity N Engl J Med 2006, 355:2249 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17124024
  3. Jump up to: 3.0 3.1 3.2 Kastrati A et al. for the ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011 Nov 13 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22077909 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1109596
  4. Jump up to: 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 16, American College of Physicians, Philadelphia 2012
  5. Jump up to: 5.0 5.1 Steg PG et al for the EUROMAX Investigators Bivalirudin Started during Emergency Transport for Primary PCI. N Engl J Med. October 30, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24171490 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1311096
    Mehta SR Balancing Thrombotic Events and Bleeding in Primary PCI. N Engl J Med. October 30, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24171491 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1312702
  6. Jump up to: 6.0 6.1 Deprecated Reference